Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas

Haematologica

Volumn 96, Issue 2, 2011, Pages 343-346

  Bedwell, Clare ^a   Rowe, David ^a   Moulton, Deborah ^b   Jones, Gail ^b   Bown, Nick ^a   Bacon, Chris M ^b,c,d  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alk positive lbcl; Sec31a alk

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN LAMBDA CHAIN; INTERFERON REGULATORY FACTOR 4; PERFORIN; PROTEIN SE31A ANAPLASTIC LYMPHOMA KINASE FUSION PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG;

AGED; ANAMNESIS; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CYTOGENETICS; DUODENUM BIOPSY; DYSPHAGIA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INGUINAL LYMPH NODE; LETTER; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MALE; NIGHT SWEAT; WEIGHT REDUCTION;

AGED; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 4; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSLOCATION, GENETIC; VESICULAR TRANSPORT PROTEINS;

EID: 79551636178     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031484     Document Type: Letter

References (8)

1. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331-56.
2. Van Roosbroeck K, Cools J, Dierickx D, Thomas J, Vandenberghe P, Stul M, et al. ALKpositive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica. 2010;95(3): 509-13.
3. Panagopoulos I, Nilsson T, Domanski HA, Isaksson M, Lindblom P, Mertens F, et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer. 2006;118(5): 1181-6.
4. Delsol G, Campo E, Gascoyne RD. ALK-positive large B-cell lymphoma. In: Serdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, editors. WHO Classification of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon: IARC Press; 2008. p. 254-5.
5. Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G, et al. Anaplastic Lymphoma Kinase-Positive Diffuse Large BCell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis. J Clin Oncol. 2009;27(25):4211-6.
6. De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood. 2003;102(7): 2638-41.
7. Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Muller-Hermelink H-K, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood. 2003;102(7):2568-73.
8. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood. 2003;102(7):2642-4